Belgium· BE-AMP-SAM519573-00
Bavencio 20 mg/ml
A avelumab product containing avelumab, registered in Belgium by Merck Europe. The same ATC class is registered in 12 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Avelumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF04 (avelumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Avelumab · ATC L01FF04
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Avelumab
- Manufacturer
- Merck Europe
- Country
- Belgium (BE)
- ATC code
- L01FF04
- ATC class
- Avelumab
- Defined daily dose
- 57.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 3
- be_apb7722929
- be_apb3705043
- be_apb4263000
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for avelumab.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Avelumab · interactions on record
3 records
- 3 severe
Most severe, free to view
- ThalidomideL04AX02severe
- LenalidomideL04AX04severe
- PomalidomideL04AX06severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Avelumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesBAVENCIOEMD Serono, Inc.
- FinlandBavencioMerck Europe B.V.
- NorwayBavencioAbacus Medicine A/S
- IcelandBavencioMerck Europe B.V.*
- CzechiaBAVENCIOMerck Europe B.V., Amsterdam
- PolandBavencioMerck Europe B.V.
- SwedenBavencio 20 mg/ml Koncentrat till infusionsvätska, lösningMerck Europe B.V.
- IrelandBavencio 20 mg/mL concentrate for solution for infusionMerck Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Bavencio
- Liechtenstein · Bavencio
- Norway · Bavencio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/96a25cbf-bbe8-4d85-a5cf-80acc4df5e56 GET /v1/drugs/96a25cbf-bbe8-4d85-a5cf-80acc4df5e56?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Bavencio 20 mg/ml",
"name_fr": "Bavencio 20 mg/ml",
"name_nl": "Bavencio 20 mg/ml",
"amp_code": "SAM519573-00",
"strengths": [
"20.0000"
],
"pack_count": 2,
"substances": [
"Avelumab",
"Mannitol",
"Sodium Hydroxide",
"Polysorbate 20"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Avelumab",
"authorisation_numbers": [
"EU/1/17/1214/001"
]
}See everything about avelumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.